Alzheimer's disease is one of the most prevalent neurodegenerative diseases. However, tools to diagnose and control the evolution of the disease are still scarce. Recently, it has been shown that curcumin has amyloid binding and fluorescent properties. Yet, the dynamics of its interactions with Alzheimer's pathological processes are still not well-known. In this study, different forms of curcumin were used to target deposits in post-mortem brain samples of different neurodegenerative diseases patients and they were compared to currently used staining methods. The researchers found that curcumin binds to amyloid-beta aggregations in Alzheimer's disease and cerebral amyloid angiopathy, but not to other protein aggregates in other neuropathologies. Immunohistochemical staining confirmed that curcumin binds to fibrillar amyloid-beta and cored plaques. Overall, it is shown that curcumin and its derivates bind selectively to fibrillar amyloid-beta and, given that curcumin is a food additive, it has a promising potential in being used coupled with imaging techniques in in vivo diagnostics in Alzheimer's disease.
Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!